Evidence map›Paper›PMID 29427237›Full record

ArticleDiabetologia2018

Differential expression of Lp-PLA2 in obesity and type 2 diabetes and the influence of lipids.

Laura Jackisch, Warunee Kumsaiyai, Jonathan D Moore, Nasser Al-Daghri, Ioannis Kyrou, Thomas M Barber, Harpal Randeva, Sudhesh Kumar, Gyanendra Tripathi, Philip G McTernan

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetologia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 3 countries.

Laura JackischDivision of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK.
Warunee KumsaiyaiDepartment of Medical Technology, Chiang Mai University, Chiang Mai, Thailand.
Jonathan D MooreWarwick Systems Biology Centre, University of Warwick, Coventry, UK.
Nasser Al-DaghriBiomarkers Research Program, Biochemistry Department, King Saud University, Riyadh, Saudi Arabia.
Ioannis KyrouDivision of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK.
Thomas M BarberDivision of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK.
Harpal RandevaDivision of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK.
Sudhesh KumarDivision of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK.
Gyanendra TripathiDivision of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK. g.tripathi@westminster.ac.uk.
Philip G McTernanDivision of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK. philip.mcternan@ntu.ac.uk.
University of Warwick · GBAston University · GBChiang Mai University · THKing Saud University · SANottingham Trent University · GBUniversity Hospitals Coventry and Warwickshire NHS Trust · GBUniversity of Westminster · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims/hypothesisLipoprotein-associated phospholipase A2 (Lp-PLA2) is a circulatory macrophage-derived factor that increases with obesity and leads to a higher risk of cardiovascular disease (CVD). Despite this, its role in adipose tissue and the adipocyte is unknown. Therefore, the aims of this study were to clarify the expression of Lp-PLA2 in relation to different adipose tissue depots and type 2 diabetes, and ascertain whether markers of obesity and type 2 diabetes correlate with circulating Lp-PLA2. A final aim was to evaluate the effect of cholesterol on cellular Lp-PLA2 in an in vitro adipocyte model.

methodsAnalysis of anthropometric and biochemical variables from a cohort of lean (age 44.4 ± 6.2 years; BMI 22.15 ± 1.8 kg/m

resultsLp-PLA2 and calcium-independent PLA2 (iPLA2) isoforms were altered by adiposity, as shown by microarray analysis (p < 0.05). Type 2 diabetes status was also observed to significantly alter gene and protein levels of Lp-PLA2 in abdominal subcutaneous (AbdSc) (p < 0.01), but not omental, adipose tissue. Furthermore, multivariate stepwise regression analysis of circulating Lp-PLA2 and metabolic markers revealed that the greatest predictor of Lp-PLA2 in non-diabetic individuals was LDL-cholesterol (p = 0.004). Additionally, in people with type 2 diabetes, oxidised LDL (oxLDL), triacylglycerols and HDL-cholesterol appeared important predictors, accounting for 59.7% of the variance (p < 0.001). Subsequent in vitro studies determined human adipocytes to be a source of Lp-PLA2, as confirmed by mRNA expression, protein levels and immunochemistry. Further in vitro experiments revealed that treatment with LDL-cholesterol or oxLDL resulted in significant upregulation of Lp-PLA2, while inhibition of Lp-PLA2 reduced oxLDL production by 19.8% (p < 0.05). CONCLUSIONS/

interpretationOur study suggests adipose tissue and adipocytes are active sources of Lp-PLA2, with differential regulation by fat depot and metabolic state. Moreover, levels of circulating Lp-PLA2 appear to be influenced by unfavourable lipid profiles in type 2 diabetes, which may occur in part through regulation of LDL-cholesterol and oxLDL metabolism in adipocytes.

Indexed as

Gene Expression Profiling1-Alkyl-2-acetylglycerophosphocholine EsteraseAdipocytesAdipose TissueAdultAnthropometryBody Mass IndexCholesterolDiabetes Mellitus, Type 2EndotoxinsFemaleGene Expression RegulationHumansInflammationLipidsLipoproteins, LDL1-Alkyl-2-acetylglycerophosphocholine EsteraseCholesterolEndotoxinsLipidsLipoproteins, LDLoxidized low density lipoproteinPLA2G7 protein, humanAdipose tissueInflammationLipidsLipoprotein-associated phospholipase A2Low density lipoproteinObesityOxidised low density lipoproteinType 2 diabetes

Identifiers

PMID29427237
PMCPMC6449000
OpenAlexW2784376069

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.